Lanreotide (Somatuline Depot)

Covered: Somatuline Depot (lanreotide) is covered only for long‑term treatment of acromegaly in patients with inadequate response to surgery/radiotherapy, who are not surgical/radiation candidates, or who have tumor‑size effects; non‑FDA/other uses are excluded. Key requirements: approval for 12 months requires a baseline IGF‑1 above the lab‑specific upper limit of normal, prescription by or consultation with an endocrinologist, starting dose 90 mg q4w for 3 months with GH/IGF‑1‑guided dose adjustments thereafter (and limited extended‑interval 120 mg q6–8w only for patients controlled on 60–90 mg), plus GH/IGF‑1 monitoring including 6‑week checks after extended‑interval changes.

"Somatuline Depot is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not ..."